Evidence map›Paper›PMID 23377435›Full record

ReviewJournal of neurology2013

Olfactory loss as a supporting feature in the diagnosis of Parkinson's disease: a pragmatic approach.

Katie Hoyles, Jagdish C Sharma

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02385500 (Randomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease Population), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02385500 phase4terminatednot on this mapstarted 2016, after this paper: background citation

Randomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease Population

TypeinterventionalSponsorSir Mortimer B. Davis - Jewish General HospitalRan2016 to 2019Enrolled5ConditionsUrinary Bladder, Overactive, Parkinson DiseaseArmsFesoterodine, Placebo
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Applicability of Sniffin' Sticks Identification Test as a Screening Tool for Olfactory Dysfunction in Northeast China.Medical science monitor : international medical journal of experimental and clinical research · 2023
    Article
  5. Recent Advances in Biomarkers for Parkinson's Disease.Frontiers in aging neuroscience · 2018
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Olfactory-related cortical atrophy is associated with olfactory dysfunction in Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Katie HoylesLincoln County Hospital, Lincoln, LN2 5QY, UK.
Jagdish C Sharma

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is ample evidence from a large number of clinical and pathological studies of an early involvement of olfactory bulbs and cortex in the Lewy body pathology in idiopathic Parkinson's disease (iPD), the olfactory system being one of the first targets of degeneration in this condition. The olfactory dysfunction may be measurably present at the time of initial presentation and progresses in a proportion of patients as the disease advances. Patients with iPD have a more severe olfactory loss as compared to multisystem atrophy whereas the syndromes of corticobasal degeneration and progressive supranuclear palsy have no olfactory loss. A proportion of drug induced parkinsonism may have olfactory loss indicative of primary pathology of dopaminergic degeneration in these patients. Unlike single photon emission tomography, formal measurement of olfaction would provide a supportive role in diagnosing or excluding iPD depending on the duration of an individual patient's parkinsonian symptoms. Whilst olfaction may be only minimally impaired in early stages and may thus not help to differentiate from other syndromes, an intact olfaction in patients with parkinsonism of few years' duration would indicate a non-iPD pathology. Olfactory measurement is easy, cheap and now easily available in a number of tests, and olfactory assessment at different stages of parkinsonism should be used as a diagnostic aid for idiopathic PD and would enhance the diagnostic accuracy of iPD when used in conjunction with the UK Parkinson's disease society Brain Bank supportive criteria for diagnosis of idiopathic Parkinson's disease.

Indexed as

HumansOlfaction DisordersParkinson Disease

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.